|
|
|
24.06.25 - 14:03
|
SELLAS Life Sciences to be Added to Russell 3000® and Russell 2000® Indexes (GlobeNewswire EN)
|
|
|
NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that the Company will be added to the Russell 3000® and Russell 2000® Indexes, effective after the U.S. market close on June 27, as part of the 2025 Russell indexes annual reconstitution....
|
|
|
|
|
|
|
|
|
|
|
20.05.25 - 14:03
|
SELLAS Life Sciences to Participate in Fireside Chat at the A.G.P. Virtual Healthcare Company Showcase (GlobeNewswire EN)
|
|
|
NEW YORK, May 20, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS'' or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that Dr. Angelos Stergiou, President and Chief Executive Officer of SELLAS, will participate in a fireside chat at the A.G.P. Virtual Healthcare Company Showcase on Wednesday, May 21, 2025 at 8:20 am ET....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
28.01.25 - 21:15
|
SELLAS Life Sciences Group Announces $25 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules (GlobeNewswire EN)
|
|
|
NEW YORK, Jan. 28, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor for the purchase and sale of 19,685,040 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 19,685,040 shares of common stock in a registered direct offering (the "Offering") at a combined purchase price of $1.27 per share and accompanying warrant, priced at-the-market under Nasdaq rules. The warrants will have an exercise price of $1.20 per share, will be immediately exercisable upon issuance and will expire 5 years from issuance....
|
|
|
|
|
|
|
02.01.25 - 14:03
|
SELLAS to Host Corporate Update Call on January 8, 2025, at 9:00 am ET (GlobeNewswire EN)
|
|
|
NEW YORK, Jan. 02, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today announced that it will host a corporate update call on Wednesday, January 8, 2025, at 9:00 a.m. Eastern Time....
|
|
|
|
|
27.11.24 - 16:44
|
Sellas rises on preclinical data for blood cancer drug (Reuters EN)
|
|
|
BUZZ-Sellas rises on preclinical data for blood cancer drug ** Cancer drug developer Sellas Life Sciences Group's SLS.O shares rise 3.7% to $1.24 ** Co says preclinical data showed its experimental drug, SLS009, demonstrated high efficacy in treating solid cancers with mutations in the ASXL1 gene ** Late last year, U.S. Food and Drug Administration...
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
